| scholarly article | Q13442814 |
| P50 | author | Albert J Fornace | Q46709984 |
| Oleg N. Demidov | Q47673190 | ||
| P2093 | author name string | Hiroshi Yamaguchi | |
| Carl W Anderson | |||
| Ettore Appella | |||
| Dmitry V Bulavin | |||
| Calvina Kek | |||
| Sathyavageeswaran Shreeram | |||
| Weng Kee Hee | |||
| P2860 | cites work | PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints | Q24527393 |
| p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation | Q24596239 | ||
| ATM: genome stability, neuronal development, and cancer cross paths | Q28201456 | ||
| Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 | Q28218453 | ||
| Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity | Q28218469 | ||
| Substrate specificity of the human protein phosphatase 2Cdelta, Wip1 | Q28243258 | ||
| Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase | Q28283888 | ||
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases | Q28581404 | ||
| DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis | Q29614217 | ||
| Atm-deficient mice: a paradigm of ataxia telangiectasia | Q29619532 | ||
| p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress | Q34717991 | ||
| Involvement of novel autophosphorylation sites in ATM activation | Q34972885 | ||
| Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis | Q35208288 | ||
| INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. | Q35208402 | ||
| Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. | Q36146840 | ||
| Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. | Q37605239 | ||
| Bim is a suppressor of Myc-induced mouse B cell leukemia | Q37647369 | ||
| Cleavage and inactivation of ATM during apoptosis. | Q38321497 | ||
| ATM activity contributes to the tumor-suppressing functions of p14ARF. | Q40534361 | ||
| ATP activates ataxia-telangiectasia mutated (ATM) in vitro. Importance of autophosphorylation | Q40662922 | ||
| E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. | Q44894517 | ||
| Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway | Q48022280 | ||
| The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice | Q57338722 | ||
| Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo | Q59098643 | ||
| Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways | Q61849111 | ||
| Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo | Q64388345 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2793-2799 | |
| P577 | publication date | 2006-12-11 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase | |
| P478 | volume | 203 |
| Q41844898 | A small molecular scaffold for selective inhibition of Wip1 phosphatase |
| Q35403658 | Absence of Wip1 partially rescues Atm deficiency phenotypes in mice |
| Q34584649 | Activation of WIP1 phosphatase by HTLV-1 Tax mitigates the cellular response to DNA damage |
| Q38963051 | Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. |
| Q37027182 | Breaking down cell cycle checkpoints and DNA repair during antigen receptor gene assembly |
| Q39763259 | Cdk2 suppresses cellular senescence induced by the c-myc oncogene. |
| Q37648742 | Cellular radiosensitivity: how much better do we understand it? |
| Q37941374 | Checkpoint control and cancer. |
| Q35158045 | DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase |
| Q34792518 | Deficiency of the tumor promoter gene wip1 induces insulin resistance |
| Q39223233 | Downregulation of Wip1 phosphatase modulates the cellular threshold of DNA damage signaling in mitosis |
| Q28079559 | Drugging the addict: non-oncogene addiction as a target for cancer therapy |
| Q37603053 | Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. |
| Q36972697 | Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors |
| Q37492244 | Facilitating replication under stress: an oncogenic function of MYC? |
| Q35940296 | Feedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System |
| Q35832016 | Genetic characterization of breast cancer and implications for clinical management |
| Q37396919 | Genetic variants and mutations of PPM1D control the response to DNA damage. |
| Q41810049 | Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3. |
| Q52657603 | Inhibition of wild-type p53-induced phosphatase 1 promotes liver regeneration in mice by direct activation of mammalian target of rapamycin. |
| Q44607719 | Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma |
| Q36446484 | Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. |
| Q37285207 | Loss of Wip1 sensitizes cells to stress- and DNA damage-induced apoptosis |
| Q33653686 | MYC and the control of DNA replication |
| Q80551010 | MYC degradation: deubiquitinating enzymes enter the dance |
| Q36403630 | Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum |
| Q28388006 | Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer |
| Q41342397 | NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. |
| Q38132359 | Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance |
| Q39930727 | PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression |
| Q35904938 | Phosphatase Wip1 controls antigen-independent B-cell development in a p53-dependent manner |
| Q37588581 | Phosphatase Wip1 in Immunity: An Overview and Update |
| Q34198570 | Phosphatases in the cellular response to DNA damage. |
| Q33693493 | Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis |
| Q33899450 | Posttranslational modification of p53: cooperative integrators of function |
| Q34654088 | Protein phosphatase magnesium-dependent 1δ (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma |
| Q60922491 | Protein phosphatases in chromatin structure and function |
| Q37554563 | Protein serine/threonine phosphatase PPEF-1 suppresses genotoxic stress response via dephosphorylation of PDCD5 |
| Q26991516 | Reaction-diffusion systems for spatio-temporal intracellular protein networks: A beginner's guide with two examples |
| Q36429982 | Regulation of the Wip1 phosphatase and its effects on the stress response. |
| Q39465762 | Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus. |
| Q36311141 | Role of Gadd45a in Wip1-dependent regulation of intestinal tumorigenesis |
| Q37788536 | Serine/threonine phosphatases in the DNA damage response and cancer |
| Q38863412 | Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma |
| Q30480882 | Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis |
| Q36712849 | The ATM signaling network in development and disease |
| Q89479770 | The role of PPM1D in cancer and advances in studies of its inhibitors |
| Q36617172 | The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. |
| Q37500944 | Thioredoxin-interacting protein regulates haematopoietic stem cell ageing and rejuvenation by inhibiting p38 kinase activity |
| Q57964115 | Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response |
| Q26745686 | Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy |
| Q90974923 | Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon |
| Q37988976 | Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance |
| Q33720757 | WIP1 phosphatase as pharmacological target in cancer therapy. |
| Q36494000 | Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis |
| Q39807046 | Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression. |
| Q39747969 | Wip1 phosphatase is associated with chromatin and dephosphorylates gammaH2AX to promote checkpoint inhibition |
| Q36012064 | Wip1 phosphatase modulates both long-term potentiation and long-term depression through the dephosphorylation of CaMKII |
| Q36338674 | Wip1 phosphatase positively modulates dendritic spine morphology and memory processes through the p38MAPK signaling pathway |
| Q26863035 | Wip1 phosphatase: between p53 and MAPK kinases pathways |
| Q35673760 | Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents |
| Q37425429 | XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center |
| Q42127661 | c-MYC-induced genomic instability. |
Search more.